1202759-74-7

Basic information

• Product Name: 2-Chloro-5-Methyl-N-(3-nitrophenyl)pyriMidin-4-aMine
• Synonyms: 2-Chloro-5-Methyl-N-(3-nitrophenyl)pyriMidin-4-aMine;(2-Chloro-5-methyl-pyrimidin-4-yl)-(3-nitro-phenyl)-amine
• CAS NO: 1202759-74-7
• Molecular Formula: C₁₁H₉ClN₄O₂
• Molecular Weight: 264.66776
• Mol File: 1202759-74-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 460.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.454±0.06 g/cm3(Predicted)
• PKA: 2.01±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-5-Methyl-N-(3-nitrophenyl)pyriMidin-4-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-Methyl-N-(3-nitrophenyl)pyriMidin-4-aMine(1202759-74-7)
• EPA Substance Registry System: 2-Chloro-5-Methyl-N-(3-nitrophenyl)pyriMidin-4-aMine(1202759-74-7)

Safety Data

• Hazardous Substances Data: 1202759-74-7(Hazardous Substances Data)

Usage

General Description

"2-Chloro-5-Methyl-N-(3-nitrophenyl)pyriMidin-4-aMine" is a chemical compound with the molecular formula C12H10ClN5O2. It is a pyrimidine derivative with a chlorine atom at the 2-position and a methyl group at the 5-position. Additionally, it contains a nitrophenyl group attached to the nitrogen atom at the 4-position. 2-Chloro-5-Methyl-N-(3-nitrophenyl)pyriMidin-4-aMine may have potential applications in pharmaceuticals, agrochemicals, or other industrial uses. Its specific properties and potential uses would need to be determined through further research and testing.

Upstream product

• 99-65-0 meta-dinitrobenzene 
• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 99-09-2 3-nitro-aniline 
• 585-79-5 m-nitrobromobenzene 
• 14394-70-8 2-chloro-4-amino-5-methylpyrimidine 

Downstream Products

• 1202759-75-8 C₁₂H₁₁ClN₄O₂ 
• 1202760-19-7 tert-butyl 3-(3-(4-(3-aminophenylamino)-5-methylpyrimidin-2-ylamino)phenoxy)propylcarbamate 
• 1202756-32-8 tert-butyl 3-(3-(4-(3-acrylamidophenylamino)-5-methylpyrimidin-2-ylamino)phenoxy)propylcarbamate 
• 1202756-19-1 N-(3-(methyl(5-methyl-2-(phenylamino)pyrimidin-4-yl)amino)phenyl)acrylamide 
• 1202759-76-9 C₁₈H₁₇N₅O₂ 
• 1202759-77-0 C₁₈H₁₉N₅ 
• 936092-80-7 5-methyl-N⁴-[3-aminophenyl]-N²-[4-(4-methylpiperazin-1-yl)phenyl]pyrimidine-2,4-diamine 
• 1202760-18-6 tert-butyl 3-(3-(5-methyl-4-(3-nitrophenylamino)pyrimidin-2-ylamino)phenoxy)propylcarbamate 

Relevant articles and documents

BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans

Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies. Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. N-(3-(5-fluoro-2- (4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl) acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quantitative assay that measures CC-292-Btk engagement has been developed. This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development. These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease. Recently, CC-292 has entered human clinical trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics. This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clinical trials. This targeted covalent drug design approach has enabled the discovery and early clinical development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders. Copyright

BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.